Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy

被引:70
作者
Principe, Daniel R. [1 ,2 ]
Narbutis, Matthew [2 ]
Kumar, Sandeep [2 ]
Park, Alex [3 ]
Viswakarma, Navin [2 ]
Dorman, Matthew J. [2 ]
Kamath, Suneel D. [4 ]
Grippo, Paul J. [5 ]
Fishel, Melissa L. [6 ]
Hwang, Rosa F. [7 ]
Thummuri, Dinesh [8 ]
Underwood, Patrick W. [9 ]
Munshi, Hidayatullah G. [4 ,10 ]
Trevino, Jose G. [9 ]
Rana, Ajay [2 ,10 ]
机构
[1] Univ Illinois, Coll Med, Med Scientist Training Program, Chicago, IL 60607 USA
[2] Univ Illinois, Dept Surg, Chicago, IL 60680 USA
[3] Univ Illinois, Coll Med, Chicago, IL USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Univ Illinois, Dept Med, Chicago, IL USA
[6] Indiana Univ, Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46204 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Breast Surg Oncol, Div Surg, Houston, TX 77030 USA
[8] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA
[9] Univ Florida, Coll Med, Dept Surg, Gainesville, FL USA
[10] Jesse Brown VA Med Ctr, Chicago, IL USA
关键词
MISMATCH REPAIR DEFICIENCY; TGF-BETA; IMMUNE EVASION; NAB-PACLITAXEL; PHASE-II; CANCER; CHEMOTHERAPY; TRIAL; ADENOCARCINOMA; BLOCKADE;
D O I
10.1158/0008-5472.CAN-19-2959
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death with a median survival time of 6-12 months. Most patients present with disseminated disease and the majority are offered palliative chemotherapy. With no approved treatment modalities for patients who progress on chemotherapy, we explored the effects of long-term gemcitabine administration on the tumor microenvironment to identify potential therapeutic options for chemorefractory PDAC. Using a combination of mouse models, primary cell line-derived xenografts, and established tumor cell lines, we first evaluated chemotherapy-induced alterations in the tumor secretome and immune surface proteins by high throughput proteomic arrays. In addition to enhancing antigen presentation and immune checkpoint expression, gemcitabine consistently increased the synthesis of CCL/CXCL chemokines and TGF beta-associated signals. These secreted factors altered the composition of the tumor stroma, conferring gemcitabine resistance to cancer-associated fibroblasts in vitro and further enhancing TGF beta 1 biosynthesis. Combined gemcitabine and anti-PD-1 treatment in transgenic models of murine PDAC failed to alter disease course unless mice also underwent genetic or pharmacologic ablation of TGF beta signaling. In the setting of TGF beta signaling deficiency, gemcitabine and anti-PD-1 led to a robust CD8(+) T-cell response and decrease in tumor burden, markedly enhancing overall survival. These results suggest that gemcitabine successfully primes PDAC tumors for immune checkpoint inhibition by enhancing antigen presentation only following disruption of the immunosuppressive cytokine barrier. Given the current lack of third-line treatment options, this approach warrants consideration in the clinical management of gemcitabine-refractory PDAC. Significance: These data suggest that long-term treatment with gemcitabine leads to extensive reprogramming of the pancreatic tumor microenvironment and that patients who progress on gemcitabine-based regimens may benefit from multidrug immunotherapy.
引用
收藏
页码:3101 / 3115
页数:15
相关论文
共 64 条
[1]   A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer [J].
Aglietta, M. ;
Barone, C. ;
Sawyer, M. B. ;
Moore, M. J. ;
Miller, W. H., Jr. ;
Bagala, C. ;
Colombi, F. ;
Cagnazzo, C. ;
Gioeni, L. ;
Wang, E. ;
Huang, B. ;
Fly, K. D. ;
Leone, F. .
ANNALS OF ONCOLOGY, 2014, 25 (09) :1750-1755
[2]   Chemotherapy Enhances Cross-Presentation of Nuclear Tumor Antigens [J].
Anyaegbu, Chidozie C. ;
Lake, Richard A. ;
Heel, Kathy ;
Robinson, Bruce W. ;
Fisher, Scott A. .
PLOS ONE, 2014, 9 (09)
[3]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[4]   Phase II study of gemcitabine in patients with advanced pancreatic cancer [J].
Carmichael, J ;
Fink, U ;
Russell, RCG ;
Spittle, MF ;
Harris, AL ;
Spiessi, G ;
Blatter, J .
BRITISH JOURNAL OF CANCER, 1996, 73 (01) :101-105
[5]   PHASE-II TRIAL OF GEMCITABINE (2,2'-DIFLUORODEOXYCYTIDINE) IN PATIENTS WITH ADENOCARCINOMA OF THE PANCREAS [J].
CASPER, ES ;
GREEN, MR ;
KELSEN, DP ;
HEELAN, RT ;
BROWN, TD ;
FLOMBAUM, CD ;
TROCHANOWSKI, B ;
TARASSOFF, PG .
INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) :29-34
[6]   The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data [J].
Cerami, Ethan ;
Gao, Jianjiong ;
Dogrusoz, Ugur ;
Gross, Benjamin E. ;
Sumer, Selcuk Onur ;
Aksoy, Buelent Arman ;
Jacobsen, Anders ;
Byrne, Caitlin J. ;
Heuer, Michael L. ;
Larsson, Erik ;
Antipin, Yevgeniy ;
Reva, Boris ;
Goldberg, Arthur P. ;
Sander, Chris ;
Schultz, Nikolaus .
CANCER DISCOVERY, 2012, 2 (05) :401-404
[7]   Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma [J].
Chen, Xinfeng ;
Wang, Liping ;
Li, Pupu ;
Song, Mengjia ;
Qin, Guohui ;
Gao, Qun ;
Zhang, Zhen ;
Yue, Dongli ;
Wang, Dan ;
Nan, Shufeng ;
Qi, Yu ;
Li, Feng ;
Yang, Li ;
Huang, Lan ;
Zhang, Mingzhi ;
Zhang, Bin ;
Gao, Yanfeng ;
Zhang, Yi .
INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (10) :2561-2574
[8]   FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer [J].
Conroy, T. ;
Hammel, P. ;
Hebbar, M. ;
Ben Abdelghani, M. ;
Wei, A. C. ;
Raoul, J. -L. ;
Chone, L. ;
Francois, E. ;
Artru, P. ;
Biagi, J. J. ;
Lecomte, T. ;
Assenat, E. ;
Faroux, R. ;
Ychou, M. ;
Volet, J. ;
Sauvanet, A. ;
Breysacher, G. ;
Di Fiore, F. ;
Cripps, C. ;
Kavan, P. ;
Texereau, P. ;
Bouhier-Leporrier, K. ;
Khemissa-Akouz, F. ;
Legoux, J. -L. ;
Juzyna, B. ;
Gourgou, S. ;
O'Callaghan, C. J. ;
Jouffroy-Zeller, C. ;
Rat, P. ;
Malka, D. ;
Castan, F. ;
Bachet, J. -B. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) :2395-2406
[9]   Algenpantucel-L immunotherapy in pancreatic adenocarcinoma [J].
Coveler, Andrew L. ;
Rossi, Gabriela R. ;
Vahanian, Nicholas N. ;
Link, Charles ;
Chiorean, E. Gabriela .
IMMUNOTHERAPY, 2016, 8 (02) :117-125
[10]   Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells [J].
Ebine, Kazumi ;
Kumar, Krishan ;
Pham, Thao N. ;
Shields, Mario A. ;
Collier, Katharine A. ;
Shang, Meng ;
DeCant, Brian T. ;
Urrutia, Raul ;
Hwang, Rosa F. ;
Grimaldo, Sam ;
Principe, Daniel R. ;
Grippo, Paul J. ;
Bentrem, David J. ;
Munshi, Hidayatullah G. .
SCIENTIFIC REPORTS, 2018, 8